Doug Melton to reunite with his Semma collaborators at Vertex to develop 'curative cell therapies'

Kyle LaHucik

Senior Reporter

A reunion is happening at Vertex Pharmaceuticals as the biopharma pushes forward its work in type 1 diabetes with a leading biologist set to join next month.

The famed Harvard stem cell researcher Doug Melton is joining the cystic fibrosis drugmaker as the company’s first “Distinguished Vertex Fellow,” according to an internal memo that Vertex shared with Endpoints News. STAT News first reported on Melton’s move.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Doug Melton to reunite with his Semma collaborators at Vertex to develop 'curative cell therapies'

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

Cash, chips and talent: Inside Nvidia's plan to dominate biotech's AI revolution

A majority of pharma and biotech companies prohibit ChatGPT use, survey finds

GSK unveils long-term Shingrix data as shingles competition heats up

Senate bill targeting WuXi won't affect federal spending, CBO says

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Regeneron enters venture investing with $500M, poaches senior partner from ARCH

Doug Melton to re­unite with his Sem­ma col­lab­o­ra­tors at Ver­tex to de­vel­op 'cu­ra­tive cell ther­a­pies'

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

more like this

Cash, chips and tal­ent: In­side Nvidi­a's plan to dom­i­nate biotech's AI rev­o­lu­tion

A ma­jor­i­ty of phar­ma and biotech com­pa­nies pro­hib­it Chat­G­PT use, sur­vey finds

GSK un­veils long-term Shin­grix da­ta as shin­gles com­pe­ti­tion heats up

Sen­ate bill tar­get­ing WuXi won't af­fect fed­er­al spend­ing, CBO says

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Re­gen­eron en­ters ven­ture in­vest­ing with $500M, poach­es se­nior part­ner from ARCH

Doug Melton to reunite with his Semma collaborators at Vertex to develop 'curative cell therapies'

Cash, chips and talent: Inside Nvidia's plan to dominate biotech's AI revolution

A majority of pharma and biotech companies prohibit ChatGPT use, survey finds

GSK unveils long-term Shingrix data as shingles competition heats up

Senate bill targeting WuXi won't affect federal spending, CBO says

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Regeneron enters venture investing with $500M, poaches senior partner from ARCH